Characterisation of the Novel HLA-A*23:163 Allele by Next-Generation Sequencing.
HLA-A*23:163 differs from HLA-A*23:01:01:03 by a single nucleotide substitution at position 925 of the cDNA.
Humans↗
SEARCH · PubMed Health
Results for “High-Throughput Nucleotide Sequencing”
Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Characterisation of the Novel HLA-B*08:01:80 Allele Identified by Next-Generation Sequencing.
HLA-B*08:01:80 differs from HLA-B*08:01:01:01 by one nucleotide substitution in exon 2-437 G>A.
Humans↗
Characterisation of the Novel HLA-C*08:01:37 Allele by Next-Generation Sequencing.
HLA-C*08:01:37 differs from HLA-C*08:01:01:01 by one single nucleotide substitution at position 927 G>A in exon 5.
Humans↗
Performance comparison of rapid and native barcoding methods for Oxford Nanopore sequencing of Poliovirus Viral Protein 1 (VP1) amplicons.
Accurate and timely sequencing of poliovirus is critical for global eradication efforts, particularly for molecular epidemiology based on the typing region of the genome, viral protein 1 (VP1). While Oxford Nanopore Technologies (ONT) sequencing has expanded capabilities for poliovirus surveillance, the relative performance of different ONT library preparation methods, including ligation-based (Native Barcoding) and transposase-based (Rapid Barcoding) approaches, has not been systematically evaluated. In this study, we compared rapid barcoding and native barcoding workflows for sequencing VP1 amplicons from 17 type 2 poliovirus-positive samples, each processed in triplicate. Native barcoding generated significantly more sequencing output, producing approximately 2.3-fold greater total read yield than rapid barcoding, and demonstrated higher run-to-run reproducibility (R2 = 0.979-0.998 vs. 0.847-0.929, respectively; p < 0.001). In addition, native barcoding generated 80% of the total yield achieved by rapid barcoding within approximately 7 h, whereas rapid barcoding required approximately 40 h to reach the same output. Despite these differences, both methods produced identical VP1 consensus sequences across all samples, with comparable read quality (median per-base Q-scores of approximately Q17-Q18). Rapid barcoding provided substantial practical advantages, reducing hands-on library preparation time (55 vs. 200 min) and per-sample cost ($12.82 vs. $16.54), while simplifying workflow and reducing technical complexity. These findings indicate that sequencing yield may not be a determinant of downstream analytical outcomes for poliovirus VP1 ONT sequencing. Rapid barcoding therefore represents a cost-effective and efficient approach for routine poliovirus surveillance, whereas native barcoding remains advantageous in applications requiring rapid data generation or maximal sequencing depth.
Poliovirus↗
Genomic Sequence of Five New Intronic Variants of HLA-DQB1*03 Characterised by Next-Generation Sequencing.
Genomic sequences of the HLA-DQB1*03:01:01:70, -DQB1*03:01:01:77, -DQB1*03:02:01:28, -DQB1*03:02:01:29, and -DQB1*03:03:02:19 alleles.
Humans↗
Using Next Generation Sequencing, Identification of the Novel Allele HLA-C*04:547 in a Saudi Individual.
The HLA-C*04:547 allele differs from HLA-C*04:04:01:01 by a single non-synonymous change in exon 7.
Humans↗
The HLA-C*12:72 Allele, Confirmed by Next-Generation Sequencing in an Indian Individual.
The HLA-C*12:72 allele, differs from HLA-C*12:02:02:01, by one nonsynonymous substitution, c.312C>A in exon 2.
Humans↗
Characterisation of the Novel HLA-A*23:23:02 Allele by Next Generation Sequencing.
HLA-A*23:23:02 differs from the most closely related allele A*23:23:01 by a single synonymous substitution in exon 3.
Humans↗
The Novel HLA-C*15:02:01:66 Allele Identified Through Next-Generation Sequencing in a Greek Individual.
The HLA-C*15:02:01:66 allele differs from HLA-C*15:02:01:01 by a single-nucleotide substitution in Intron 6.
Humans↗
Identification of the Novel HLA-B*55:135 Allele by Next-Generation Sequencing.
Compared with the HLA-B*55:04 allele, HLA-B*55:135 shows two nucleotide substitutions in exon 2 (codon 63 AAC>GAG).
Humans↗
Identification of the Novel HLA-A*02:540:02N Allele by Next-Generation Sequencing.
HLA-A*02:540:02N differs from A*02:01:01:01 by one nucleotide substitution in codon 99 in exon 3.
Humans↗
The Novel HLA-C*07:1193 Allele Was Identified by Next-Generation Sequencing.
HLA-C*07:1193 differs from HLA-C*07:02:01:03 in exon 5 codon 292 (GCT>GTT).
Humans↗
The Novel HLA-DQB1*06:03:60 Allele Identified by Next-Generation Sequencing and Confirmed by Nanopore Sequencing.
HLA-DQB1*06:03:60 differs from HLA-DQB1*06:03:01:01 by a single synonymous nucleotide substitution at position 174 in Exon 2.
Humans↗
Discovery of the Novel HLA-DQB1*05:386 Allele in a Brazilian Volunteer Donor.
HLA-DQB1*05:386 differs from HLA-DQB1*05:01:01:01 by a non-synonymous substitution in exon 4.
Humans↗
The Novel HLA-DQA1*03:63 Allele Was Identified by Next-Generation Sequencing.
HLA-DQA1*03:63 differs from HLA-DQA1*03:02:01:01 by a single nucleotide substitution at position 722 G>A.
Humans↗
The Novel HLA-A*02:1229 Allele Was Identified by Next-Generation Sequencing.
HLA-A*02:1229 differs from HLA-A*02:07:01:01 by a single nucleotide substitution at position 1014 T>A.
Humans↗
Discovery of the Novel HLA-DPA1*02:02:02:22 Allele Through Next-Generation Sequencing.
The HLA-DPA1*02:02:02:22 allele differs from HLA-DPA1*02:02:02:01 by a single nucleotide substitution in intron 1.
Humans↗
Identification of the Novel HLA-DQB1*02:02:41 Allele by Next-Generation Sequencing.
HLA-DQB1*02:02:41 differs from HLA-DQB1*02:02:01:01 by one synonymous nucleotide substitution at Codon 39 in Exon 2.
Humans↗